214 related articles for article (PubMed ID: 29232390)
21. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
22. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
23. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
24. Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.
Burad DK; Kodiatte TA; Rajeeb SM; Goel A; Eapen CE; Ramakrishna B
World J Gastroenterol; 2016 Oct; 22(40):8956-8966. PubMed ID: 27833387
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A predicts survival for resected pancreatic neuroendocrine tumors.
Shanahan MA; Salem A; Fisher A; Cho CS; Leverson G; Winslow ER; Weber SM
J Surg Res; 2016 Mar; 201(1):38-43. PubMed ID: 26850182
[TBL] [Abstract][Full Text] [Related]
26. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin.
Mai R; Kaemmerer D; Träger T; Neubauer E; Sänger J; Baum RP; Schulz S; Lupp A
Sci Rep; 2019 Mar; 9(1):4339. PubMed ID: 30867449
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
[TBL] [Abstract][Full Text] [Related]
28. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
[TBL] [Abstract][Full Text] [Related]
29. A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms.
Kruljac I; Vurnek I; Maasberg S; Kust D; Blaslov K; Ladika Davidović B; Štefanović M; Demirović A; Bišćanin A; Filipović-Čugura J; Marić Brozić J; Pape UF; Vrkljan M
Endocrine; 2018 Jun; 60(3):395-406. PubMed ID: 29633144
[TBL] [Abstract][Full Text] [Related]
30. The Role of Plasma Chromogranin A as Assessment of Treatment Response in Non-functioning Gastroenteropancreatic Neuroendocrine Tumors.
Kim M; Lee S; Lee J; Park SH; Park JO; Park YS; Kang WK; Kim ST
Cancer Res Treat; 2016 Jan; 48(1):153-61. PubMed ID: 25779359
[TBL] [Abstract][Full Text] [Related]
31. Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.
Donica H; Malecha-Jędraszek A; Strosławska E; Burska A; Szubstarski F
Folia Histochem Cytobiol; 2010 Dec; 48(4):603-10. PubMed ID: 21478104
[TBL] [Abstract][Full Text] [Related]
32. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological features of colorectal neuroendocrine neoplasms and prognostic significance of WHO staging system].
Zhang XH; Lu XL; Wu N; Liu B; Wang FY; Zhang RS; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Mar; 42(3):191-6. PubMed ID: 23769440
[TBL] [Abstract][Full Text] [Related]
34. Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms.
Kidess E; Giesecke Y; Eichhorn I; Mohr R; Jann H; Fischer C; Wiedenmann B; Roderburg C; Tacke F; Sigal M
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10925-10933. PubMed ID: 37318593
[TBL] [Abstract][Full Text] [Related]
35. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
36. [Neuroendocrine neoplasms of the breast].
Anlauf M; Neumann M; Bomberg S; Luczak K; Heikaus S; Gustmann C; Antke C; Ezziddin S; Fottner C; Pavel M; Pape UF; Rinke A; Lahner H; Schott M; Cremer B; Hörsch D; Baum RP; Groh U; Alkatout I; Rudlowski C; Scheler P; Zirbes TK; Hoffmann J; Fehm T; Gabbert HE; Baldus SE
Pathologe; 2015 May; 36(3):261-70. PubMed ID: 25986886
[TBL] [Abstract][Full Text] [Related]
37. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
38. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.
Modlin IM; Drozdov I; Kidd M
PLoS One; 2013; 8(5):e63364. PubMed ID: 23691035
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia.
Kečkéš Š; Palaj J; Waczulíková I; Dyttert D; Mojtová E; Kováč G; Durdík Š
In Vivo; 2021; 35(5):2863-2868. PubMed ID: 34410979
[TBL] [Abstract][Full Text] [Related]
40. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
